Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 1-Year High – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $11.53 and last traded at $11.51, with a volume of 224844 shares trading hands. The stock had previously closed at $11.29.

Analyst Upgrades and Downgrades

BAYRY has been the subject of a number of research analyst reports. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The stock has a market capitalization of $45.35 billion, a P/E ratio of -128.21, a price-to-earnings-growth ratio of 5.58 and a beta of 0.66. The business’s 50 day simple moving average is $9.54 and its two-hundred day simple moving average is $8.55. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.